Janux Therapeutics reports third quarter net loss of $24.3 million

Reuters

2025/11/07

Janux <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $24.3 million

Janux Therapeutics Inc. reported cash and cash equivalents and short-term investments of $989.0 million as of September 30, 2025, compared to $1.0 billion at December 31, 2024. Research and development expenses for the third quarter of 2025 were $34.6 million, up from $18.6 million in the same period in 2024. General and administrative expenses were $10.6 million, compared to $17.7 million for the third quarter of 2024, with the previous year's figure including $9.5 million in stock-based compensation expense. Net loss for the quarter ended September 30, 2025, was $24.3 million, compared to $28.1 million in the prior year period. During the period, Janux continued enrollment for its Phase 1 clinical trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced or metastatic solid tumors. Additional data updates for both programs are expected in the fourth quarter of 2025. The company is also advancing additional candidates from its TRACTr, TRACIr, and ARM platforms toward future clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106163122) on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581012798"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581012798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581012798?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581012798","market":"us","top_or_hot":-1,"title":"Janux Therapeutics reports third quarter net loss of $24.3 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter net loss of $24.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Janux Therapeutics Inc. reported cash and cash equivalents and short-term investments of $989.0 million as of September 30, 2025, compared to $1.0 billion at December 31, 2024. Research and development expenses for the third quarter of 2025 were $34.6 million, up from $18.6 million in the same period in 2024. General and administrative expenses were $10.6 million, compared to $17.7 million for the third quarter of 2024, with the previous year's figure including $9.5 million in stock-based compensation expense. Net loss for the quarter ended September 30, 2025, was $24.3 million, compared to $28.1 million in the prior year period. During the period, Janux continued enrollment for its Phase 1 clinical trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced or metastatic solid tumors. Additional data updates for both programs are expected in the fourth quarter of 2025. The company is also advancing additional candidates from its TRACTr, TRACIr, and ARM platforms toward future clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106163122) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janux Therapeutics reports third quarter net loss of $24.3 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanux Therapeutics reports third quarter net loss of $24.3 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter net loss of $24.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Janux Therapeutics Inc. reported cash and cash equivalents and short-term investments of $989.0 million as of September 30, 2025, compared to $1.0 billion at December 31, 2024. Research and development expenses for the third quarter of 2025 were $34.6 million, up from $18.6 million in the same period in 2024. General and administrative expenses were $10.6 million, compared to $17.7 million for the third quarter of 2024, with the previous year's figure including $9.5 million in stock-based compensation expense. Net loss for the quarter ended September 30, 2025, was $24.3 million, compared to $28.1 million in the prior year period. During the period, Janux continued enrollment for its Phase 1 clinical trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced or metastatic solid tumors. Additional data updates for both programs are expected in the fourth quarter of 2025. The company is also advancing additional candidates from its TRACTr, TRACIr, and ARM platforms toward future clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106163122) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3DS7Nn:1","article_id":"2581012798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581012798","pubTimestamp":1762462930,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Janux Therapeutics Inc. reported cash and cash equivalents and short-term investments of $989.0 million as of September 30, 2025, compared to $1.0 billion at December 31, 2024. Research and development expenses for the third quarter of 2025 were $34.6 million, up from $18.6 million in the same period in 2024. General and administrative expenses were $10.6 million, compared to $17.7 million for the third quarter of 2024, with the previous year's figure including $9.5 million in stock-based compensation expense. Net loss for the quarter ended September 30, 2025, was $24.3 million, compared to $28.1 million in the prior year period. During the period, Janux continued enrollment for its Phase 1 clinical trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced or metastatic solid tumors. Additional data updates for both programs are expected in the fourth quarter of 2025. The company is also advancing additional candidates from its TRACTr, TRACIr, and ARM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","JANX":"Janux Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"Janux Therapeutics报告第三季度净亏损2430万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JANX":0.9},"content_text":"Janux Therapeutics reports third quarter net loss of $24.3 million\n    \n\n        Janux Therapeutics Inc. reported cash and cash equivalents and short-term investments of $989.0 million as of September 30, 2025, compared to $1.0 billion at December 31, 2024. Research and development expenses for the third quarter of 2025 were $34.6 million, up from $18.6 million in the same period in 2024. General and administrative expenses were $10.6 million, compared to $17.7 million for the third quarter of 2024, with the previous year's figure including $9.5 million in stock-based compensation expense. Net loss for the quarter ended September 30, 2025, was $24.3 million, compared to $28.1 million in the prior year period. During the period, Janux continued enrollment for its Phase 1 clinical trials of JANX007 in metastatic castration-resistant prostate cancer and JANX008 in advanced or metastatic solid tumors. Additional data updates for both programs are expected in the fourth quarter of 2025. The company is also advancing additional candidates from its TRACTr, TRACIr, and ARM platforms toward future clinical development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106163122) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}